Healthequity Inc (NASDAQ:HQY) EVP Gary D. Robinson sold 1,500 shares of the company’s stock in a transaction dated Thursday, April 5th. The shares were sold at an average price of $63.85, for a total transaction of $95,775.00. Following the sale, the executive vice president now directly owns 4,490 shares in the company, valued at $286,686.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
NASDAQ:HQY opened at $65.91 on Wednesday. Healthequity Inc has a fifty-two week low of $40.21 and a fifty-two week high of $68.75. The company has a market cap of $3,913.12, a PE ratio of 122.06, a P/E/G ratio of 2.57 and a beta of 1.39.
Healthequity (NASDAQ:HQY) last announced its quarterly earnings results on Monday, March 19th. The company reported $0.06 EPS for the quarter, hitting analysts’ consensus estimates of $0.06. Healthequity had a return on equity of 13.47% and a net margin of 20.64%. The company had revenue of $60.44 million during the quarter, compared to analyst estimates of $58.46 million. sell-side analysts forecast that Healthequity Inc will post 0.77 EPS for the current year.
Several research firms recently weighed in on HQY. KeyCorp upped their price objective on shares of Healthequity from $66.00 to $72.00 and gave the stock an “overweight” rating in a research report on Thursday, April 5th. Zacks Investment Research cut shares of Healthequity from a “buy” rating to a “hold” rating in a research report on Wednesday, April 4th. ValuEngine upgraded shares of Healthequity from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. Cantor Fitzgerald reiterated a “buy” rating and set a $65.00 price target on shares of Healthequity in a research report on Friday, March 23rd. Finally, Barrington Research increased their price target on shares of Healthequity to $65.00 and gave the company an “outperform” rating in a research report on Tuesday, March 20th. Two equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $66.50.
Hedge funds have recently made changes to their positions in the stock. Global X Management Co. LLC lifted its position in Healthequity by 180.6% during the fourth quarter. Global X Management Co. LLC now owns 36,601 shares of the company’s stock valued at $1,708,000 after buying an additional 23,556 shares during the period. Amussen Hunsaker Associates LLC lifted its position in Healthequity by 1.9% during the third quarter. Amussen Hunsaker Associates LLC now owns 237,239 shares of the company’s stock valued at $12,000,000 after buying an additional 4,493 shares during the period. Signition LP purchased a new position in Healthequity during the fourth quarter valued at $348,000. California Public Employees Retirement System lifted its position in Healthequity by 7.5% during the fourth quarter. California Public Employees Retirement System now owns 103,028 shares of the company’s stock valued at $4,807,000 after buying an additional 7,169 shares during the period. Finally, Dimensional Fund Advisors LP lifted its position in Healthequity by 12.2% during the third quarter. Dimensional Fund Advisors LP now owns 531,288 shares of the company’s stock valued at $26,872,000 after buying an additional 57,855 shares during the period. 99.17% of the stock is owned by institutional investors.
HealthEquity, Inc provides a range of solutions for managing healthcare accounts (Health Savings Accounts (HSAs), Health Reimbursement Arrangements (HRAs) and Flexible Spending Accounts (FSAs)) for health plans, insurance companies and third-party administrators. The Company is engaged in technology-enabled services platforms that allow consumers to make healthcare saving and spending decisions.
Receive News & Ratings for Healthequity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healthequity and related companies with MarketBeat.com's FREE daily email newsletter.